



China Shineway received more invention patents

China Shineway has recently received two more invention patents issued by the Intellectual Property Office of the PRC.

The first invention patent relates to the application of total triterpenes of centella asiatica in preventing chronic renal failure and membranous nephropathy while improving the kidney function. The second invention patent is award to a modernized Chinese medicine made out of natural ingredients, including radix rehmanniae, radix astragali, cortex eucommiae, carthamus tinctorius and radix codonopsis, for treatment of prostatic hyperlasis. The patented medicine has overcome the disadvantage of western medicine in toxicities, known side effect and high price. Products offered by China Shineway under these two invention patents would benefit patients with related kidney and prostate diseases.

China has fixed the roadmap in the development of the health care industry

The State Council of PRC has recently announced “The Outline of the Eleventh Five-Year Plan for the Health Care Industry”. Pursuant to the Outline, China will strengthen its effort in developing the traditional Chinese medicines (“TCM”) industry with emphasis on the importance to use both TCM and western medicines and practices as well as to equalize their respective developments. The Outline also states that the PRC government will increase its investments in the TCM industry and establish policies to support the continuous development in TCM service network, innovation capabilities and modernization of TCM.